Protein Modification Reagents
Ambeed Fmoc-NH-PEG12-CH2CH2COOH | 1952360-91-6 | 840.0 g/mol |
Fmoc-NH-PEG12-CH2CH2COOH | 1952360-91-6 | 840.0 g/mol |
Medchemexpress LLC Pomalidomide-PEG4-C2-NH2 hydrochloride | 2357105-92-9 | 98.2% | 528.98 | 250 MG
Pomalidomide-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate. It incorporates the Pomalidomide-based cereblon ligand and a 4-unit PEG linker, used in the synthesis of PROTACs. PROTACs utilize an E3 ubiquitin ligase ligand and a target protein ligand, exploiting the ubiquitin-proteasome system to selectively degrade target proteins. This product is for research use only.
- Synthesized E3 ligase ligand-linker conjugate
- Incorporates Pomalidomide-based cereblon ligand
- Features a 4-unit PEG linker
- Used in the synthesis of PROTACs
- Targets cereblon
- For research use only
Broadpharm Sulfo DBCO-PEG4-Maleimide | 2055198-07-5 | MFCD30458040 | 100mg
Sulfo DBCO-PEG4-Maleimide | Putity: 90% | MW: 825.9 | 2055198-07-5 | MFCD30458040 | 100mg
Medchemexpress LLC Mal-amido-PEG8-C2-acid | 1334177-86-4 | MFCD13184956 | 98.7% | 592.63 g·mol-1 | C26H44N2O13 | 250 MG
Mal-amido-PEG8-C2-acid is a maleimide-functionalized PEG8 linker designed for stable, non-cleavable conjugation of payloads to thiol-containing biomolecules. It provides a hydrophilic spacer to improve solubility and reduce aggregation during antibody-drug conjugate and bioconjugation workflows.
- Maleimide group for selective thiol conjugation.
- PEG8 spacer to improve solubility and reduce aggregation.
- Non-cleavable linker to provide stable payload attachment.
- High purity suitable for research and development use (≈98.7%).
- Solid form for straightforward handling and storage.
Medchemexpress LLC Pomalidomide-peg4-c2-nh2 hydrochloride | 2357105-92-9 | 98.2% | 528.98 | 1 G
Pomalidomide-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a 4-unit PEG linker, used in the synthesis of PROTACs. It is for research use only and not sold to patients.
- PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein.
- PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
- These methods are for reference only.